Cargando…

Home Immunization with Palivizumab-A Randomized Pilot Study Describing Safety Aspects and Parents’ Preferences

Among prematurely born infants and newborns with chronic conditions, a respiratory syncytial virus (RSV) infection may cause (re-)admission and later respiratory complications. Therapeutic protection is possible with monthly injections of a specific monoclonal antibody, palivizumab, during RSV seaso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ebersjö, Christina, Berggren Broström, Eva, Kull, Inger, Lindholm Olinder, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955059/ https://www.ncbi.nlm.nih.gov/pubmed/36832327 http://dx.doi.org/10.3390/children10020198

Ejemplares similares

Treatment with pollen allergen immunotherapy improves health-related quality of life in children and adolescents: a three-year follow-up-study
por: Agenäs, Helena, et al.
Publicado: (2023)

YKL‐40 is a proposed biomarker of inflammation and remodelling elevated in children with bronchopulmonary dysplasia compared to asthma
por: James, Anna J., et al.
Publicado: (2020)

The Medicaid Cost of Palivizumab
por: Ambrose, Christopher S., et al.
Publicado: (2015)

Oral health problems linked to obstructive sleep apnea are not always recognized within dental care—As described by dental professionals
por: Berggren, Kristina, et al.
Publicado: (2021)

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children
por: al-Alaiyan, Saleh, et al.
Publicado: (2015)

Randomized, Double-Blind Study of the Pharmacokinetics and Safety of Palivizumab Liquid Formulation Compared with Lyophilized Formulation
por: Robbie, Gabriel J., et al.
Publicado: (2014)

Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease
por: O’Hagan, Shaun, et al.
Publicado: (2023)

Development of a palivizumab specialty pharmacy management program
por: Harlan, Lana, et al.
Publicado: (2019)

Is immunization with palivizumab really effective in high-risk children?
por: Raguž, Marjana Jerković, et al.
Publicado: (2023)

Studies Recommending Palivizumab Restriction Have Serious Deficiencies
por: Stewart, Dan L.
Publicado: (2010)

How parents describe the positive aspects of parenting their child who has intellectual disabilities: A systematic review and narrative synthesis
por: Beighton, Carole, et al.
Publicado: (2019)

Cost effectiveness of palivizumab in Spain: an analysis using observational data
por: Nuijten, Mark J., et al.
Publicado: (2009)

Neonatal outcomes following new reimbursement limitations on palivizumab in Italy
por: Belleudi, Valeria, et al.
Publicado: (2018)

Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study
por: Rajapaksa, Anushi E., et al.
Publicado: (2020)

Reappraisal of the Subtropical Guidelines on Palivizumab Prophylaxis in Congenital Heart Disease
por: Chiu, Shuenn-Nan, et al.
Publicado: (2022)

Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era
por: Taylor, Richard S.
Publicado: (2021)

A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis
por: Frogel, Michael
Publicado: (2010)

A virtual clinic for the management of diabetes-type 1: study protocol for a randomised wait-list controlled clinical trial
por: Nerpin, Elisabet, et al.
Publicado: (2020)

Respiratory infections in children up to two years of age on prophylaxis with palivizumab
por: Monteiro, Ana Isabel M. P., et al.
Publicado: (2014)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
por: Olchanski, Natalia, et al.
Publicado: (2018)

Reducing Palivizumab Dose Requirements Through Rational Dose Regimen Design
por: Reuter, Stephanie E., et al.
Publicado: (2018)

Guided self-determination-young versus standard care in the treatment of young females with type 1 diabetes: study protocol for a multicentre randomized controlled trial
por: Haas, Josephine, et al.
Publicado: (2017)

Types and Aspects of Front-of-Package Labeling Preferred by Parents: Insights for Policy Making in China
por: Cui, Jia, et al.
Publicado: (2022)

Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review
por: Wegzyn, Colleen, et al.
Publicado: (2014)

Impact of Palivizumab on RSV Hospitalizations for Children with Hemodynamically Significant Congenital Heart Disease
por: Chang, Ruey-Kang R., et al.
Publicado: (2009)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Respiratory Syncytial Virus Infection in High-risk Infants – an Update on Palivizumab Prophylaxis
por: Resch, Bernhard
Publicado: (2014)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
por: Resch, Bernhard
Publicado: (2017)

Impact of the use of immunoglobulin palivizumab in the State of São Paulo: a cohort study
por: Gonçalves, Ivana Regina, et al.
Publicado: (2017)

Human respiratory syncytial virus and other viral infections in infants receiving palivizumab
por: Boivin, Guy, et al.
Publicado: (2008)

Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review
por: Belleudi, Valeria, et al.
Publicado: (2021)

Compliance with The RSV Immunoprophylaxis Dosing Schedule in The Polish Registry for Palivizumab (2008-2014)
por: Borecka, Róża, et al.
Publicado: (2019)

Post-translational modifications and glycoprofiling of palivizumab by UHPLC–RPLC/HILIC and mass spectrometry
por: Sran, Kulwinder Singh, et al.
Publicado: (2022)

Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab
por: Manini, Mariana Bueno, et al.
Publicado: (2021)

A post-incorporation study on the use of palivizumab in the Brazilian public health system
por: Batista, Joanna d’Arc Lyra, et al.
Publicado: (2021)

Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children
por: Viguria, Natividad, et al.
Publicado: (2021)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Describing randomisation: patients' and the public's preferences compared with clinicians' practice
por: Jenkins, V, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_112h09bvtd4me4becukd02429u